Real-World Clinical Utility of Tumor Whole-Genome Sequencing in Solid Cancers

Research published in Nature Medicine on April 2, 2026, indicates that routine, paired tumor-normal whole-genome sequencing (WGS) provides significant clinical utility for patients with solid cancers. The study, which analyzed data from 888 patients at a comprehensive cancer center, found that WGS serves as a tumor-agnostic solution for identifying a complex range of DNA-based biomarkers.

The diagnostic process succeeded in 89% of the cases, with a median turnaround time of six working days. Researchers identified potentially actionable biomarkers in 73% of the patients. These biomarkers included options for experimental therapies in 63% of cases and reimbursed therapies in 27% of cases.

Impact on Treatment and Survival

Within one year of testing, 40% of patients with biomarkers for reimbursed therapies and 19% of patients with biomarkers for experimental therapies began biomarker-informed treatment.

The application of biomarker-informed treatment was associated with a 31% increase in median overall survival, representing an additional 96 days compared to patients who did not receive such therapy.

The survival benefits were more pronounced among patients who had not previously received systemic therapy. In this group, those receiving biomarker-informed treatment saw a median overall survival that was not reached during the study period. In contrast, patients receiving non-biomarker-informed therapy had a median overall survival of 427 days, while those receiving no systemic therapy had a median overall survival of 214 days.

Addressing Cancers of Unknown Primary

The study specifically examined 123 patients with cancers of unknown primary. For 67% of these patients, WGS contributed to a diagnostic solution or identified reimbursed treatment options driven by biomarkers.

68% of the patients with cancers of unknown primary were able to start therapy specific to their tumor type based on the sequencing results.

Genetic and Clinical Findings

Beyond tumor-specific markers, the WGS diagnostics identified clinically relevant pathogenic germline variants in 6.5% of the patients.

the study concluded that WGS-based diagnostics resulted in clinical consequences for 41% of the tested patients, suggesting the technology is a versatile tool for routine clinical practice in solid oncology.

This finding aligns with broader research into genomic alterations. A separate prospective, single-center study of 120 patients with solid cancers reported that WGS could offer a feasible single-assay approach to replace targeted panel sequencing. In that study, 72% of reports yielded clinically relevant insights, with 69% pertaining to therapeutic actionability and 81% pertaining to clinical clarity.

The integration of WGS into clinical settings allows for the identification of driver mutations, mutational signatures, and tumor mutational burden (TMB), which can be used to select informed therapeutics or active clinical trials.